Resuscitative Endovascular Balloon Occlusion of the Aorta — a temporizing bridge to definitive hemorrhage control for non-compressible torso trauma
Non-compressible torso hemorrhage (NCTH) — bleeding from the abdomen, pelvis, or junctional zones that cannot be controlled with direct pressure or a tourniquet — remains the leading cause of preventable death after trauma. REBOA and resuscitative (emergency department) thoracotomy with aortic cross-clamping are the two endovascular/surgical options for gaining proximal aortic control before the patient reaches the operating room, and choosing between them depends heavily on injury mechanism, physiologic status, and signs of life.
Non-compressible torso hemorrhage (NCTH) refers to bleeding sources — solid organ injury (liver, spleen), pelvic fracture with venous plexus and arterial disruption, retroperitoneal vascular injury, or junctional wounds at the groin/axilla — that lie outside the reach of a tourniquet or wound packing. Because direct compression is impossible, the only ways to stop the bleeding are (1) definitive surgical or angiographic hemostasis, or (2) temporary proximal vascular control that reduces flow to the bleeding source until definitive control can be achieved.
Aortic occlusion, whether via open thoracotomy and cross-clamp or endovascular balloon, works by interrupting antegrade aortic blood flow distal to the clamp/balloon. This immediately reduces flow (and therefore ongoing blood loss) from an intra-abdominal or pelvic bleeding source, while simultaneously redirecting the finite circulating blood volume toward the heart and brain — increasing coronary perfusion pressure and cerebral perfusion pressure in a patient who may be moments from cardiovascular collapse. This is the same physiologic principle exploited in both a cross-clamped aorta at thoracotomy and an inflated REBOA balloon; REBOA simply achieves it through a femoral catheter rather than a scalpel and rib spreader.
The single most important variable determining REBOA candidacy is the presence of "signs of life": palpable pulse, pupillary response, spontaneous respiratory effort, organized cardiac electrical activity, or measurable blood pressure at any point during the resuscitation, even if the patient later loses these signs. REBOA is designed for patients in profound but not yet arrested hemorrhagic shock — a systolic blood pressure under roughly 90 mmHg (often much lower) with a plausible abdominal, pelvic, or junctional bleeding source, who still have a perfusing rhythm the balloon can augment.
Resuscitative (ED) thoracotomy, by contrast, is classically reserved for patients who arrest or are peri-arrest in the emergency department, particularly those with penetrating thoracic trauma and recent (within minutes) loss of signs of life — the scenario in which opening the chest allows direct cardiac massage, release of pericardial tamponade, control of a thoracic hemorrhage source, and cross-clamping of the descending thoracic aorta. Outcomes data consistently show thoracotomy survival is dramatically better for penetrating mechanism with witnessed arrest (roughly 10–15%) than for blunt trauma or prolonged pre-hospital CPR (survival approaching zero in several large series).
In practice, many trauma centers now view REBOA and thoracotomy as complementary rather than competing tools along a spectrum of physiologic decline: REBOA for the patient in extremis but not arrested with a sub-diaphragmatic source, thoracotomy for the arrested or peri-arrest patient — especially with a penetrating thoracic mechanism where direct cardiac and pulmonary hilar control is needed.
REBOA is relatively contraindicated in known or suspected thoracic aortic injury (traumatic aortic transection/dissection), since balloon inflation proximal to an injured aortic segment risks catastrophic extension of the injury or free rupture. It is also poorly suited to isolated thoracic hemorrhage (hemothorax, pulmonary hilar injury, cardiac injury) because occluding the abdominal aorta does nothing to control bleeding above the diaphragm — this is a scenario favoring thoracotomy instead.
Other relative limitations include cardiac arrest with no organized rhythm (the balloon has no downstream perfusion to augment), inability to obtain femoral access (severe peripheral vascular disease, bilateral lower extremity amputation, prior extensive groin surgery), and situations in which the bleeding source is itself proximal to the intended occlusion zone (e.g., a Zone I balloon does nothing for a subclavian or axillary arterial injury).
Successful REBOA begins and often fails at the femoral artery. Rapid, reliable common femoral artery (CFA) access under time pressure, in a hypotensive and sometimes coagulopathic patient, is technically the most demanding step of the entire procedure — and device miniaturization over the past decade has meaningfully lowered the barrier to success.
Modern REBOA protocols strongly favor ultrasound-guided percutaneous access over blind palpation or open femoral cutdown, particularly in hypotensive patients where the femoral pulse may be faint or absent. A linear high-frequency probe identifies the CFA proximal to its bifurcation into superficial femoral and profunda femoris branches — cannulating below this bifurcation risks smaller-vessel injury and makes hemostasis at sheath removal more difficult.
A micropuncture technique (21-gauge needle, 0.018" wire, 4 Fr micropuncture sheath) is generally preferred to minimize arterial wall trauma, followed by an upsizing exchange to the definitive REBOA sheath over a stiffer 0.035" guidewire. In the peri-arrest patient, some centers perform open femoral cutdown/exposure to guarantee vessel visualization when ultrasound-guided puncture fails or time does not permit repeated attempts — a decision that trades speed for reliability.
Device miniaturization has been one of the most important advances in REBOA's clinical adoption: first-generation aortic occlusion balloons required 11–14 Fr sheaths, sized similarly to some cardiac surgical cannulae, and carried substantial risk of femoral arterial thrombosis and limb ischemia purely from the access itself. Current-generation low-profile devices (e.g., the ER-REBOA catheter) function through a 7 Fr sheath — comparable in caliber to many cardiac catheterization sheaths — meaningfully reducing access-site vascular complications while preserving balloon occlusion performance.
Once the sheath is secured, the balloon catheter is advanced retrograde through the external and common iliac artery into the aorta. Positioning can be estimated using external body-surface landmarks correlated with typical adult anatomy (a widely used approximation: roughly 28–34 cm of catheter insertion from the CFA places the balloon tip in Zone III; roughly 45–50 cm reaches Zone I), then ideally confirmed with a portable anteroposterior chest/abdominal radiograph or fluoroscopy before inflation, since blind, landmark-only positioning carries a real risk of inflating in the wrong zone or across a branch vessel origin.
Some newer REBOA devices incorporate an integrated pressure-monitoring lumen at the catheter tip, allowing the operator to transduce a real-time arterial pressure waveform from the aortic segment distal to the balloon — both confirming intra-aortic (rather than iliac or venous) position before inflation and providing continuous distal pressure feedback during occlusion that is otherwise unavailable at the bedside.
Inflating a balloon across the aorta is, from the heart's perspective, an abrupt and severe increase in afterload layered onto an already compromised circulation. Understanding this physiology — and the rationale for partial rather than full occlusion — is central to using REBOA safely rather than trading exsanguination for a different lethal complication.
Full aortic occlusion abruptly increases left ventricular afterload — the pressure the heart must generate to eject blood — while simultaneously boosting coronary and cerebral perfusion pressure, which is precisely why it can be lifesaving in profound shock: a heart that was perfusing itself and the brain poorly now perfuses both much better, buying time. But this benefit is not free. In a volume-depleted, often acidotic and cold heart, the sudden afterload surge can precipitate acute left ventricular strain, pulmonary edema if volume resuscitation runs ahead of the physiology, and dysrhythmia risk, particularly in patients with pre-existing cardiac disease or prolonged pre-occlusion shock.
Zone I occlusion (thoracic aorta, effectively supraceliac positioning at the level of practice) occludes essentially the entire abdominal, pelvic, and lower-extremity vascular bed distal to the balloon — producing the largest proximal blood pressure augmentation but also the most extensive ischemic burden, since it excludes the mesenteric, renal, and lower-body circulations simultaneously. Zone III occlusion (infrarenal) spares the celiac, superior mesenteric, and renal arteries, producing a smaller, more localized rise in proximal pressure but exposing only the pelvis and lower extremities to ischemia — a favorable trade-off when the injury is confined to the pelvis or a junctional lower-extremity wound.
Every minute of full aortic occlusion accrues an ischemic and metabolic debt in the tissue distal to the balloon — skeletal muscle, gut mucosa, and (for Zone I) the kidneys and viscera — that must eventually be "repaid" when flow is restored. Anaerobic metabolism in ischemic tissue generates lactate and hydrogen ions; cell membrane integrity fails over time, releasing potassium and myoglobin; and the longer the ischemic interval, the more severe the reperfusion injury when the balloon is deflated.
Based on animal models and accumulated clinical registry experience, most REBOA protocols treat full aortic occlusion as safe for roughly 30 minutes or less, with 60 minutes widely cited as an outer ceiling beyond which the risk of severe metabolic acidosis, acute kidney injury, rhabdomyolysis, and irreversible distal limb or organ ischemia rises sharply. These are not sharp cutoffs but a continuum of accumulating risk — the goal at every point during occlusion is to be actively working toward definitive hemorrhage control (operating room or angiography suite), not to treat REBOA itself as the treatment.
Partial REBOA (pREBOA) is a refinement in which the balloon is deliberately under-inflated relative to full occlusion, permitting a small, controlled trickle of antegrade distal aortic flow rather than complete cessation. The goal is to retain most of the proximal blood-pressure augmentation benefit of full occlusion while substantially slowing the accumulation of distal ischemic and metabolic debt — in effect stretching the usable, safe occlusion window from tens of minutes toward multiple hours in controlled series and animal studies.
Titration is typically guided by distal arterial pressure monitoring (via a pressure-sensing catheter lumen or a separate distal arterial line) or by balloon volume adjustment against a target proximal blood pressure, aiming for enough distal flow to limit ischemic injury while still meaningfully reducing hemorrhage from the injury source. Purpose-built partial-occlusion devices (e.g., the pREBOA-PRO catheter) are designed around this titration concept, with a balloon and shaft profile intended to make graded, reproducible partial inflation practical at the bedside rather than an improvised maneuver on a full-occlusion-only device.
REBOA is not a benign intervention layered onto an already critically ill trauma patient — it carries a distinct complication profile spanning the access site, the occluded vascular bed, and the systemic consequences of reperfusion, and recognizing these risks is essential to using the technique judiciously rather than reflexively.
Because REBOA requires a relatively large-bore arterial sheath in a vessel that is often already compromised by shock-related vasoconstriction and hypoperfusion, the femoral access site itself is a recognized source of morbidity. Reported complications include common femoral artery thrombosis, arterial dissection during wire or sheath passage, pseudoaneurysm formation, and distal embolization of thrombus formed around the indwelling sheath. Risk scales with sheath caliber — a major reason the shift from 11–14 Fr first-generation devices to 7 Fr low-profile catheters has been an important safety advance — and with the duration the sheath remains in place.
Meticulous post-procedure vascular surveillance (distal pulse checks, Doppler assessment, low threshold for formal vascular surgery consultation or surgical repair) is standard practice after sheath removal, particularly in patients who required prolonged access.
The distal vascular bed excluded by the balloon — lower extremities always, plus mesenteric and renal circulations with Zone I occlusion — experiences a period of near-complete or complete ischemia proportional to occlusion duration and completeness. Consequences can include acute kidney injury from renal hypoperfusion (particularly with Zone I occlusion or prolonged Zone III occlusion causing systemic hypoperfusion), skeletal muscle ischemia progressing to rhabdomyolysis with myoglobin release, and in severe or prolonged cases, irreversible limb ischemia requiring fasciotomy or amputation.
The risk of these complications rises steeply with occlusion time and with the extent of the vascular bed excluded — underscoring why Zone III is preferred over Zone I whenever the injury pattern allows, and why partial occlusion strategies exist specifically to blunt this category of harm.
Deflating the balloon after a period of occlusion abruptly reintroduces blood flow to a large, ischemic, acidotic tissue bed — and with it, a bolus of accumulated lactate, hydrogen ions, potassium, and inflammatory mediators returning to the central circulation. This "ischemia-reperfusion syndrome" can manifest as an abrupt drop in blood pressure (loss of the proximal augmentation combined with a sudden vasodilatory and myocardial-depressant load), acute severe metabolic acidosis, life-threatening hyperkalemia with associated dysrhythmia, and acute lung injury from circulating inflammatory mediators.
Standard mitigation strategies include slow, incremental (rather than instantaneous) balloon deflation, ensuring adequate volume resuscitation and vasopressor availability before deflation begins, having calcium, bicarbonate, and hyperkalemia treatment immediately available, and — whenever feasible — favoring partial occlusion strategies that reduce the magnitude of the ischemic debt that must be reversed.
REBOA entered widespread civilian trauma practice substantially ahead of high-quality comparative outcomes data — a sequence common in trauma innovation, but one that has generated real and ongoing debate about which patients actually benefit, and by how much, compared with existing standards of care.
Much of the foundational outcomes data on REBOA comes from multi-center observational registries, most notably the AAST-supported AORTA (Aortic Occlusion for Resuscitation in Trauma and Acute care surgery) registry, which pools REBOA cases from trauma centers across multiple countries. These registries have been essential for characterizing real-world technical success rates, complication frequencies, and time-to-hemorrhage-control benchmarks, but as observational rather than randomized data, they are inherently limited by selection bias: sicker, more hemodynamically unstable patients are more likely to receive REBOA in the first place, which can make outcome comparisons against non-REBOA cohorts difficult to interpret at face value.
Early registry analyses comparing REBOA to resuscitative thoracotomy produced genuinely mixed mortality findings — some suggesting a survival advantage for REBOA in appropriately selected patients, others finding no difference or even a signal toward worse outcomes, often attributable to differences in injury severity and physiologic status between the compared groups rather than the intervention itself.
The UK-REBOA trial, a pragmatic multi-center randomized controlled trial published in JAMA in 2023, represented the first randomized evidence directly comparing standard major hemorrhage protocol care with and without REBOA in patients with suspected exsanguinating torso hemorrhage. Its results were sobering for REBOA proponents: the trial did not demonstrate a mortality benefit for REBOA, and mortality in the REBOA arm was numerically higher than in the standard-care arm, prompting early trial termination on the recommendation of the data monitoring committee.
This result has reframed — but not eliminated — the role of REBOA in contemporary practice. Proposed explanations include the time cost of the REBOA procedure itself potentially delaying transfer to definitive hemorrhage control, inclusion of patients whose physiology or injury pattern may not have represented ideal REBOA candidates, and the trial's inherent difficulty controlling for operator experience and procedural speed across many participating centers. The trial has intensified rather than resolved debate, and most trauma surgery guidance now emphasizes narrower, more careful patient selection alongside minimizing occlusion time, rather than either abandoning or broadly expanding REBOA use.
Current research and practice trends center on three themes: (1) refining patient selection criteria so that REBOA is reserved for the subset of patients most likely to benefit — profound shock with a plausible sub-diaphragmatic source and preserved signs of life — rather than being used as a default maneuver in any hypotensive trauma patient; (2) partial occlusion (pREBOA) strategies aimed at preserving the physiologic benefit while reducing ischemic complication rates, an area of active device development and clinical study; and (3) system-level factors, including operator training, procedural speed, and minimizing any delay to definitive surgical or angiographic hemorrhage control that REBOA might introduce.
The overall trajectory of the evidence supports treating REBOA as a selectively used, time-limited bridge — powerful in the right patient at the right moment, but not a substitute for rapid definitive hemorrhage control, and not free of the potential to cause harm when used indiscriminately or left inflated too long.
Every element of REBOA's design and use — the ischemia clock, the preference for partial over full occlusion when possible, the emphasis on rapid transfer to the operating room or angiography suite — reflects a single unifying idea: the balloon is a temporizing measure, not a treatment for the underlying injury.
REBOA does not repair a lacerated spleen, does not reduce and stabilize a fractured pelvis, and does not embolize a bleeding branch of the internal iliac artery. What it does is convert a patient who might otherwise exsanguinate and arrest during transport or while awaiting the operating room into one whose heart and brain are adequately perfused for the minutes required to reach a location where the actual bleeding source can be controlled — the operating room for surgical hemostasis and packing, or the angiography suite for selective embolization of a pelvic or solid-organ arterial injury.
Every design choice discussed in this simulation reflects that framing: the ischemia clock exists because the bridge has a structural time limit; partial occlusion (pREBOA) exists to extend that limit without abandoning the physiologic benefit; and the entire procedural workflow — rapid access, targeted zone selection, expedited transfer — is organized around minimizing the time the balloon needs to remain inflated before the patient reaches definitive care.